Insider Trading Activity For Crispr Theraptc (NASDAQ:CRSP)

Tyler Dylan-Hyde , Insider of Crispr Theraptc (NASDAQ:CRSP) reportedly Sold 15,000 shares of the company’s stock at an average price of 18.57 for a total transaction amount of $278,550.00 SEC Form

Insider Trading History For Crispr Theraptc (NASDAQ:CRSP)

On 10/24/2016 Simeon George, Director, bought 66,500 with an average share price of $14.00 per share and the total transaction amounting to $931,000.00.View SEC Filing

On 10/24/2016 Corp /De/ Celgene, Major Shareholder, bought 800,150 with an average share price of $14.00 per share and the total transaction amounting to $11,202,100.00.View SEC Filing

On 4/20/2017 Tyler Dylan-Hyde, Insider, sold 10,177 with an average share price of $17.71 per share and the total transaction amounting to $180,234.67.View SEC Filing

On 4/20/2017 Rodger Novak, CEO, sold 50,000 with an average share price of $17.88 per share and the total transaction amounting to $894,000.00.View SEC Filing

On 4/25/2017 Samarth Kulkarni, Insider, sold 11,615 with an average share price of $16.78 per share and the total transaction amounting to $194,899.70.View SEC Filing

On 4/27/2017 Samarth Kulkarni, Insider, sold 5,481 with an average share price of $16.76 per share and the total transaction amounting to $91,861.56.View SEC Filing

On 4/28/2017 Tyler Dylan-Hyde, Insider, sold 21,639 with an average share price of $16.78 per share and the total transaction amounting to $363,102.42.View SEC Filing

Analyst Ratings For Crispr Theraptc (NASDAQ:CRSP)
These are 4 Hold Ratings, 4 Buy Ratings .
The current consensus rating for Crispr Theraptc (NASDAQ:CRSP) is Buy (Score: 2.50) with a consensus target price of $21.92 , a potential (16.95% upside)

Analyst Ratings History For Crispr Theraptc (NASDAQ:CRSP)

• On 11/14/2016 Barclays PLC Initiated Coverage of rating Overweight with a price target of $22.00
• On 11/14/2016 Guggenheim Initiated Coverage of rating Buy with a price target of $30.00
• On 11/15/2016 Citigroup Inc. Initiated Coverage of rating Neutral with a price target of $19.00
• On 2/16/2017 Piper Jaffray Companies Set Price Target of rating Buy with a price target of $21.00
• On 3/27/2017 Chardan Capital Initiated Coverage of rating Buy to Buy with a price target of $23.50
• On 7/13/2017 SunTrust Banks, Inc. Initiated Coverage of rating Hold to Hold with a price target of $16.00
• On 7/17/2017 Cann Initiated Coverage of rating Market Perform

Recent Trading Activity for Crispr Theraptc (NASDAQ:CRSP)
Shares of Crispr Theraptc closed the previous trading session at 18.74 up +0.24 1.30% with 146,378 shares trading hands.